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The ability to monitor and manipulate antigen-specific immune responses would have a major impact on
several areas of biology and medicine. In this perspective, I consider pharmacological methods to do this,
with a focus on the development of abiological ‘‘antigen surrogates’’ capable of binding to the antigen-bind-
ing sites of antibodies and B cell receptors with high affinity and selectivity. I describe the application of
combinatorial library screening to identify antigen surrogates for monoclonal antibodies of therapeutic inter-
est using chronic lymphocytic leukemia as an example. Furthermore, I discuss the use of multiplexed assays
for the quantification of antigen surrogate-antibody complexes as diagnostic tools and antigen surrogate
discovery via serum screening. Although antigen surrogates are a fairly new concept, I argue that they will
open new avenues for both basic and clinical research and that major advances can be expected over the
next few years.Antigen-Specific Immune Responses in Therapeutics
and Diagnostics
The manipulation of antigen-specific immune responses is com-
mon in clinical medicine. By far the most important example is
vaccination. Most vaccines introduce to the host immune sys-
tem antigens derived from a pathogen. The resultant proliferation
of antibodies and T cells that recognize these antigens affords
protection from a subsequent infection by that pathogen. Exten-
sion of the vaccine concept to noninfectious diseases, especially
cancers, is an active area of research. The idea is to identify
tumor-specific antigens and vaccinate people with these to
hyperactivate cancer-specific immune responses (Palucka and
Banchereau, 2014). There has also been exciting recent prog-
ress in engineering artificial antigen-specific immune responses
by introducing into the patients’ own T cells engineered chimeric
receptors that recognize specific cancer antigens and trigger
activation of the T cells. The engineered cells are then reintro-
duced to patients, in whom they attack tumors (Barrett et al.,
2014). These technologies are focused on stimulating an im-
mune response to a particular antigen. The flip side, eliminating
or dampening responses to particular antigens through toleriza-
tion strategies (Roep et al., 2013), is of interest for the treatment
of autoimmune disease.
All of these technologies use biological strategies to manipu-
late antigen-specific immune responses. A little-explored alter-
native strategy would be to develop drugs that do so. This would
require ‘‘antigen surrogates,’’ that is, synthetic compounds
capable of binding tightly and selectively to the antigen-binding
site of an antibody, B cell receptor (BCR), or T cell receptor (TCR)
(Figure 1). A high-affinity ligand of this type could potentially
block access of an antigen to its cognate receptor. Alternatively,
an antigen surrogate could be tethered to some effector mole-
cule, for example a toxin, resulting in a chimeric reagent capable
of killing only pathogenic lymphocytes (Figure 1). This would
represent an interesting advance over the current state of the
art in pharmacological manipulation of lymphocytes, such as
the ability of rituximab, an anti-CD20 therapeutic monoclonal1066 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltantibody, to kill all B cells (Edwards et al., 2004) (Figure 1). Alter-
natively, it might be possible to vaccinate patients with an anti-
gen surrogate (Caulfield et al., 2010; Knittelfelder et al., 2009).
Antibodies that recognize the surrogate might also have signifi-
cant affinity for the native antigen of interest. This synthetic
vaccine strategy would be quite useful in eliciting an immune
response against a poorly immunogenic antigen or one that is
difficult to prepare in large quantities.
Many investigators also believe that the adaptive immune
response is a potential treasure trove of diagnostic biomarkers
(Anderson and LaBaer, 2005). The underlying hypothesis is
that many disease states are likely to produce molecules that
are not present in healthy people, such as unusual posttransla-
tionally modified proteins, and that the adaptive immune system
will react to these species as foreign antigens. The resultant dis-
ease antigen-specific antibodies or cells would thus serve as
attractive biomarkers. As discussed later, powerful genomic
and proteomic methods to identify these putative antibody bio-
markers are being explored, but thesemethods do not shed light
on the native antigen. Yet to develop a practical and inexpensive
clinical test to measure the levels of these antibodies, one re-
quires a ‘‘capture agent’’ that can be immobilized on an ELISA
plate or the like to retain the biomarker antibody from the serum.
High-affinity and high-selectivity antigen surrogates would be
ideal for this application.
In this perspective, I presents progress to date in the discovery
and use of effective antigen surrogates, as well as discuss likely
future directions in this area. I focus entirely on targeting soluble
antibodies and BCRs. TCR targeting, which is also feasible
(Gocke et al., 2009) is not discussed here.
Identification of Antigen Surrogates for Monoclonal
Antibodies of Therapeutic Interest through
Combinatorial Library Screening
The simplest route to antigen surrogates would be to screen a
suitable compound collection against a monoclonal antibody
that one would like to target for therapeutic or diagnosticd All rights reserved
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Figure 1. A Potential Therapeutic Application of Antigen Surrogates
to Monitor or Treat CLL
(A) A single antigen-specific B lymphocyte is amplified relentlessly in CLL. Yet
because CLL B cells are deficient in differentiation into plasmablasts, the
soluble antibody form of the BCR of the pathogenic cell is not present in the
circulation (Chiorazzi et al., 2005).
(B) The state of the art in current pharmacological manipulation of B cells
results in killing all CD20+ cells through the use of rituximab or similar mono-
clonal antibodies (red). An antigen surrogate coupled to a toxin or a molecule
that recruits effector functions (Murelli et al., 2009) could, in theory, eliminate
only pathogenic B cells without affecting the healthy function of the humoral
immune system.
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most important when the native antigen is unknown or imprac-
tical to use as a targeting agent or diagnostic tool.
On the therapeutic side, a good example would be chronic
lymphocytic leukemia (CLL) (Chiorazzi et al., 2005). In CLL, a
single antigen-specific B cell clone is amplified relentlessly,
crowding out healthy B cells from lymph nodes and other im-
mune centers, eventually forming a tumor. Moreover, CLL B cells
are defective for differentiation into antibody-producing plasma
cells, so these patients lack high levels of soluble antibodies cor-
responding to the pathogenic BCRs. This makes the CLL BCR a
potentially interesting target for drugs that would deliver a cyto-
toxic moiety to them, sparing healthy B cells and thus allowing
for continued function of normal humoral immune responses
during treatment (Figure 1). DNA sequencing of heavy-chain
complementarity-determining region (CDR) 3 of thousands of
CLL BCRs has revealed that about 35% can be grouped into
sequence-related families called stereotypes (Agathangelidis
et al., 2012), strongly suggesting that the amplification of these
B cells is the result of a response to a limited number of autoan-
tigens. However, with one exception (Chu et al., 2010), the iden-
tities of these suspected antigens are unknown. Thus, one would
require antigen surrogates to develop the type of targeted toxins
mentioned above. One could also imagine roles for compounds
that target antigen-specific immunoglobulin E monoclonal anti-
bodies in blocking allergic responses (Handlogten et al., 2011).
Antigen surrogates that bind monoclonal antibodies will also
be interesting reagents for diagnostic purposes. As mentioned
previously, there is significant interest in mining the adaptive im-
mune response, and especially antibodies, for disease-specific
biomarkers. Recently, advances have been made in methods
to sort many thousands of individual B cells into small wells,Chemistry & Biology 2allowing native heavy and light pairing to be retained (Laserson
et al., 2014; Tan et al., 2014). The CDR sequences of either the
heavy or light chain, or both, of each BCR clone can then be
determined by sequencing the corresponding cDNA (Georgiou
et al., 2014). If this experiment is donewith several case and con-
trol patients, then antibody consensus sequences restricted to
the case population can be discovered, and patient-to-patient
variability can be assessed. Although sequencing BCR-encod-
ing genes could possibly be done as a clinical assay, it would
be preferable to develop a simple ELISA protocol. Unfortunately,
this genomics-driven discovery approach does not provide any
insight into the native antigens recognized by the disease-
restricted antibodies. Therefore, a high-affinity, selective antigen
surrogate would be quite useful in developing a simple ELISA-
like diagnostic test in which it is used as the capture agent to
retain the antibody of interest from a patient serum sample.
There is no question that the discovery of antigen surrogates is
feasible. Indeed, there is a considerable literature on peptide
‘‘mimitopes’’ isolated from different types of combinatorial pep-
tide libraries that have a modest affinity for antibodies whose
native antigens are not peptides (sugars, etc.) (Knittelfelder
et al., 2009). Relevant to the CLL example provided above, a
recent paper reported the identification of peptide ligands for
the soluble immunoglobulin G (IgG) form of a CLL BCR from a
phage display library (Seiler et al., 2009). However, the feasibility
of identifying nonpeptidic, more drug-like compounds with high
affinity and selectivity for antigen-binding sites is less clear.
Because there is no obvious high-throughput functional assay
with which to screen for antibody/BCR ligands, the most
straightforward way to approach this problem is to use a binding
assay using small molecules displayed in either a microarray
format (MacBeath et al., 1999) or on the surface of hydrophilic
beads (Liu et al., 2002). The latter format is especially attractive
because large one-bead one-compound (OBOC) libraries of
certain types of unnatural oligomeric compounds such as pep-
toids or b-peptides can be produced readily using solid-phase
split and pool synthesis (Figliozzi et al., 1996). For example,
my laboratory has elaborated the classical ‘‘submonomer’’ syn-
thesis of peptoids (Zuckermann et al., 1992) (oligomers of
N-substituted glycines) to facilitate the creation of peptoid-
inspired compounds with more chemically complex and confor-
mationally restricted main chain scaffolds (Figure 2) (Aditya and
Kodadek, 2012; Aquino et al., 2012; Gao and Kodadek, 2013;
Sarma et al., 2011; Suwal and Kodadek, 2013). Very recently,
we screened one such library (Figure 2) against several soluble
IgG forms of CLL BCRs (M. Sarkar, Y. Liu, J. Morimoto, H.
Peng, C. Aquino, C. Rader, N. Chiorazzi, and T.K., unpublished
data). This library was largely built using a COPA (chiral oligo-
mers of pentenoic amides) scaffold, developed by Micalizio
and coworkers (Aquino et al., 2012). Because of strong allylic
1,3 strain interactions, the COPA units greatly stiffen the main
chain of the molecule relative to peptides or peptoids. Thus,
even small COPA oligomers fold into stable structures deter-
mined by the absolute stereochemistry at the chiral center
(Aquino et al., 2012). About 1.3 million beads displaying diverse
tetramers were screened by first incubating the OBOC library
with a mixture of antibodies from patients without CLL. Beads
that retained significant amounts of antibody were visualized
by the addition of a fluorescently labeled secondary antibody,1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1067
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Figure 2. Peptoid-Inspired, Conformationally Constrained Oligomers Provide a Valuable Source of Antigen Surrogates
(A) Structures of acid submonomers that have been developed for use in the peptoid submonomer scheme (box). The 2-oxopiperazine and diketopiperazine
structures are made in a multistep sequence on the resin rather than being true submonomers (Suwal and Kodadek, 2013).
(B) A combinatorial library that was used to screen for antigen surrogates that bind to the soluble IgG form of CLL BCRs. The library is composed of a peptoid unit
followed by three COPA units. The structures of the amine submonomers used are shown. The library contained approximately 1.3 million different compounds
(M. Sarkar, Y. Liu, J. Morimoto, H. Peng, C. Aquino, C. Rader, N. Chiorazzi, and T.K., unpublished data).
(C) Schematic representation of the screening protocol used to mine antigen surrogates from a combinatorial library. The OBOC library is first exposed to a large
number of human IgG antibodies obtained from healthy volunteers. Beads that retain significant levels of antibody are detected by subsequent incubation with a
red quantumdot-labeled secondary antibody. These beads, which display antibody ligands that are not of interest, are removed from the library. The remainder of
(legend continued on next page)
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(Figure 2). The remainder of the library was then incubated with
three monoclonal CLL IgGs, and, again, the hits were identified
using a fluorescent secondary antibody. Antigen surrogates
with good affinity and selectivity were identified for two of the
three targets. For example, the compound KMS5, shown in
Figure 2, bound to the CLL 169 IgG with a KD of approximately
90 nM and did not show significant affinity for other IgGs with
different antigen-binding sites. Efforts are under way to improve
the affinity of the molecule for the BCR. Importantly, when KMS5
was mounted onto a biotinylated dextran polymer, it bound with
high affinity and selectivity to patient-derived CLL 169 B cells,
but not to B cells displaying other antigen-specific antibodies
(M. Sarkar, Y. Liu, J. Morimoto, H. Peng, C. Aquino, C. Rader,
N. Chiorazzi, and T.K., unpublished data). To the best of my
knowledge, this is the first example of a synthetic, unnatural
molecule recognizing an antigen-specific lymphocyte. As such,
it constitutes a critical first step in the development of chimeric
molecules of the type shown in Figure 1B. It is interesting to
note that the CLL 169 IgGwas also used as the target of a screen
using a 12-residue phage-displayed peptide library (Seiler et al.,
2009). The best ligands to arise from this screen were of similar
affinity to the smaller, proteolytically stable synthetic oligomer.
Multiplexed Assays for the Quantification of Antigen
Surrogate-Antibody Complexes as Diagnostic Tools
As mentioned previously, next-generation DNA sequencing-
based methods to analyze the repertoire of large numbers of in-
dividual immunoglobulin-producing cells is proceeding at a rapid
rate (Georgiou et al., 2014). Although few such studies have been
done yet, one can imagine that this technique will soon be used
to identify antibodies that distinguish case and control popula-
tions for many disease states. These antibodies could then be
expressed recombinantly and serve as targets for antigen surro-
gate screens of the type discussed previously for CLL. Although
these are still early days, the promising results obtained in the
CLL study (M. Sarkar, Y. Liu, J. Morimoto, H. Peng, C. Aquino,
C. Rader, N. Chiorazzi, and T.K., unpublished data) raise the
hope that when presented with a monoclonal antibody, the iden-
tification of antigen surrogates with good affinity and selectivity
will soon be fairly routine. In anticipation of this workflow
becoming more important, my research group has developed
a highly multiplexed ‘‘liquid array’’ platform optimized for
measuring interactions between small molecules and serum an-
tibodies (Figure 3) (Doran and Kodadek, 2014). This system was
inspired by the Luminex platform (Vignali, 2000), in which latex
microspheres displaying a particular ligand on their surface (usu-
ally a nucleic acid or antibody) are encoded by the adsorption of
specific concentrations and ratios of two different colored dyes
in the interior of the bead. This system is useful for multiplexed
sandwich assays in which an immobilized antibody binds an an-
alyte, whose level is then measured by the addition of a labeled
sandwich antibody. The analysis is done using a specialized flowthe beads are then screened against the antibody of interest, in this case the so
collected. The compounds are released from the bead via cyanogen bromide-m
structure is determined bymass spectrometry (Sarkar et al., 2013). The structure o
(a particular patient-derived BCR), is shown. This proved to be a 500 nM ligand fo
plate, the difference presumably reflecting avidity effects on the plate.
Chemistry & Biology 2cytometer-like instrument with three lasers, two of which ‘‘read’’
the bead’s encoding dyes, with the third irradiating the dye on
the sandwich antibody. This system is suboptimal for the anal-
ysis of serum antibodies using immobilized small molecules,
however (Doran and Kodadek, 2014). First, when one attempts
to do organic chemistry on these beads, the dyes leach out
rapidly in organic solvents, resulting in loss of the color code.
Second, there is a high degree of nonspecific binding of serum
antibodies to the beads. We solved both of these problems by
using 10 mm TentaGel microspheres as the solid support, which
consist of an amine-functionalized polystyrene core with a thick
outer coating of amine-terminated polyethylene glycol (PEG)
chains. Lam and coworkers developed a protocol by which
one can do chemistry selectively on the interior or exterior do-
mains of these beads (Liu et al., 2002). We used this technique
to immobilize particular ratios of Pacific Blue and Pacific Orange
covalently to the interior of the bead, which is not exposed to
proteins, to encode. The small-molecule capture agent was
then affixed to the hydrophilic outer layer. The thick PEG coating
results in a very low degree of nonspecific binding. Moreover, the
density of the small molecule ligand on the surface of the bead
is sufficient that both arms of an antibody engage ligands,
providing higher affinity through an avidity effect (Doran and Ko-
dadek, 2014). After incubation of the beads with a serum sample,
they are washed, incubated with a labeled secondary antibody
labeledwith a third color, washed again, and then analyzed using
a standard flow cytometer. In our published work, we demon-
strated the ability to analyze 24 different antibody-small mole-
cule complexes simultaneously (Doran and Kodadek, 2014),
but subsequent improvements to the protocol have more than
doubled this number.
Looking into the future, then, the rapidly expanding power
of immunogenomics is likely to provide increasing numbers of
diagnostically useful monoclonal antibodies. I believe it is likely
that over the next few years, the ability to identify high-affinity
and high-selectivity antigen surrogates capable of retaining
these antibodies from serum will become routine. Combined
with the existing analytical technology mentioned earlier, one
can foresee an exciting future in which more and more important
diseases are diagnosed through the use of multiplexed immuno-
assays using synthetic capture agents. Finally, because there is a
reasonable expectation that immune responses against disease
states are likely to occur early in the pathogenic process, there is
the hope that this type of technology would enable the develop-
ment of a new kind of presymptomatic diagnostics inwhich these
kind of highly multiplexed antibody detection assays could be
performed each time a patient comes in for an annual physical.
Antigen Surrogates fromSerumScreening: ThePromise
and Challenge of Screening Combinatorial Libraries
against Complex, Polyclonal Antibody Populations
As mentioned previously, deep sequencing of lymphocyte pop-
ulations is likely to facilitate the discovery of diagnosticallyluble IgG form of a BCR from a CLL patient. The hits are again identified and
ediated cleavage of the methionine residue in the conserved linker and the
f the highest affinity hit, KMS5, whichwas obtained in a screen against CLL 169
r the IgG form of the BCR in solution and 90 nM when immobilized on an ELISA
1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1069
Figure 3. Luminex-like Liquid Array
Platform for the Multiplexed Analysis of
Small Molecule-Antibody Interactions
(A) Schematic of the biphasic TentaGel micro-
sphere-based system. The hydrophobic interior
domain of the beads is modified covalently with a
particular concentration and ratio of two dyes,
Pacific Blue and Pacific Orange. The hydrophilic
outer layer of the bead, which is exposed to
solution, is modified with the antigen surrogate
capture agent. When exposed to serum, the
amount of antibody captured by the antigen sur-
rogate is quantified by subsequent incubation with
a secondary antibody labeled with a third color.
(B) Illustration of bead sorting and fluorescence
‘‘reading’’ using a common flow cytometer
requiring two excitation lasers and three de-
tectors.
(C) A typical data plot showing the ratiometric
emission intensities of the two encoding dyes.
Each subpopulation can be separated from a
batch of differentially dyed microspheres.
(D) Upon gating a designated subpopulation,
binding can be quantified as the relative intensity
of a reporter fluorochrome (dye 3).
(E) Fluorescence-activated cell sorting dot plot
of Pacific Orange versus Pacific Blue emission
intensities for a batch of 24 subpopulations of
encoded microspheres.
(F) Comparison of Luminex versus TentaGel plat-
forms in serological measurements. (Left) Binding
isotherms generated for the detection of anti-
ADP3 immunoglobulin Y (IgY) in chicken serum
using ADP3 immobilized onto TentaGel micro-
spheres. Binding was quantified by measuring the
mean fluorescence intensity (MFI) of a phycoery-
thrin-conjugated anti-IgY antibody. (Right) The
same experiment was performed using ADP3 im-
mobilized onto Luminex microspheres. Reprinted
with permission from Doran and Kodadek (2014).
Chemistry & Biology
Perspectiveinteresting antibodies. But it is not the only path to this goal.
Indeed, an issue with this approach, as pointed out by Georgiou
et al. (2014), is that the readily accessible, circulating peripheral
B cells represent only a small fraction of the immune repertoire.
What one would really like to do is to screen the circulating anti-
body population itself for biomarkers. Therefore, there is
continued interest in other methods to tackle this problem.
Some efforts are already being made to use deep sequencing
data to enable the interpretation of mass spectra of antibody-
derived tryptic peptides to find those corresponding to the vari-
able regions. It will be interesting to see how applicable this
approach is to biomarker discovery (Boutz et al., 2014). The
most common approach to antibody profiling currently available
is to screen case and control antibody populations against some
collection of candidate disease-specific antigens and identify
one that binds antibodies rich in the case population but absent
in the control population (Figure 4). In other words, it is a search
for the antigen, not an antigen surrogate. This type of experiment
has been done with proteome arrays (Lueking et al., 2003;1070 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltd All rights reservedNagele et al., 2011; Robinson et al.,
2003), lipid arrays (Kanter et al., 2006), ar-
rays created from chromatographic frac-
tions of tissue lysates (Qiu et al., 2004),
and a variety of other tools. Somewhatsimilar in approach is the use of peptide libraries for this applica-
tion (Restrepo et al., 2011; Robinson et al., 2002; Wang et al.,
2005). Of course, large random peptide libraries or those made
from mRNA via shearing-based methods will be composed
mostly of sequences not found in the proteome (Wang et al.,
2005), but nonetheless the hope inmost such efforts is to identify
peptides that would closely resemble a native linear epitope.
Although these efforts have had some success, a rush of use-
ful antibody biomarkers has not resulted from this work. Why this
is so is not clear. One hypothesis is that, outside of infectious
diseases and some autoimmune conditions, the most useful
antibody biomarkers might result from an adaptive immune
response against unusually modified proteins or other antigens,
for example, oxidized species. If so, these antigens would not be
present in collections of ‘‘vanilla’’ proteins, peptides, or most
other biomolecule collections, and the search would largely
fail. With this idea in mind, my research group decided to explore
a different idea, which was to carry out differential case versus
control screens on libraries of unnatural molecules in the hope
Figure 4. Searching for Ig Biomarkers via
Hybridization of Serum to Arrays of
Antigens or Antigen Surrogates
All such experiments involve exposing some
collection of molecules arrayed on chemically
modified glass slides to case and control serum
samples that contain all circulating antibodies.
After washing, the degree of antibody binding to
each feature of the array is determined by subse-
quent hybridization of a labeled secondary anti-
body (a green dye in this schematic) and scanning
of the array. The goal is to identify features on the
array that capture significantly more antibody from
the case sera than the control sera. Three spots
are highlighted (indicated by arrows) to illustrate
this idea. The hypothetical biomarker antibody is
colored pink in this figure.
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most interesting disease-specific antigens (Reddy et al., 2011).
Initially, this experiment was done using an animal model sys-
tem for MS (multiple sclerosis) called EAE (experimental autoim-
mune encephalomyelitis). This involves immunizing a mouse
with a 21-residue peptide derived from the murine nerve sheath
protein MOG (myelin oligodendrocyte glycoprotein), along with
an appropriate adjuvant to break tolerance and thus drive an
autoimmune attack, reproducing some aspects of MS. Sera
from EAE mice or control mice were hybridized to planar glass
microarrays displaying 8,600 octameric peptoids taken from a
combinatorial library created by solid-phase split and pool
chemistry (Figure 4). Several peptoids were identified that were
subsequently shown to bind to the anti-MOGpeptide antibodies,
but not to other murine antibodies with different antigen-binding
sites (Reddy et al., 2011). Excellent diagnostic sensitivity and
specificity could be achieved bymonitoring IgG antibody binding
to these peptoids. These data demonstrated that the antigen
surrogate concept is indeed extendable to serum antibody
screening and biomarker discovery, at least in this simple dis-
ease model.
Of course, murine EAE is a very simple disease model, and it
is not difficult to imagine why this approach might fail when
applied to human disease. In the EAE model, the antigen is a
single, modest-sized peptide. For any human disease, there
will surely exist many antigens, and many might be large pro-
teins with several epitopes. If so, one would expect a complex,
polyclonal immune response. Although I have used the term
‘‘antigen surrogate’’ in this article, the relatively small molecules
that we are using would most likely serve as a surrogate for a
particular epitope of a larger antigen. If the antibody population
is highly polyclonal, it might be difficult to see a strong signal in
the case versus control screen, because each molecule might
bind only a fraction of this polyclonal spectrum. Also, because
these antigen surrogates must interact with a given antigen-
binding pocket differently than does the native antigen, it could
be that the antigen surrogate relies on contacts with residues
that are unimportant for native antigen recognition. If so, thenChemistry & Biology 21, September 18, 2014 ªit is possible that an antigen surrogate
might have a highly restricted binding
profile even to the polyclonal population
of antibodies that all bind the samenative epitope. This raises the specter that an antigen surrogate
that recognizes an antibody in patient A would not cross-react
with an antibody in patient B, even if patients A and B have an-
tibodies to the same native epitope. Indeed, this complex issue
of polyclonality makes antigen surrogate discovery via serum
screening a completely different and far more difficult game
than library screens against a single protein target. Finally, there
are potentially major issueswith the clinical samples themselves.
Those provided by different centers may have been collected or
stored under different conditions, affecting antibody stability. Or
the clinical diagnosis could simply be wrong. This is a major
concern in many neurological conditions and other areas of
medicine in which diagnoses are made largely on the basis of
symptoms. Even in diseases in which reliable gold standards
for diagnosis exist, such as the detection of colon cancer by
colonoscopy, how many different molecular pathways might
exist to produce that phenotype? If it is ten, then presumably
the adaptive immune system might react to each by producing
different antibodies, and a simple case versus control screen
with ten patients would be unlikely to provide obvious hits.
Even given all of these concerns, we conducted a modest test
of the idea in Alzheimer’s disease (AD). Again, an array of 8,600
peptoids was used to screen IgG antibodies in 6 AD patients,
6 Parkinson’s disease (PD) patients, and 6 nondemented,
age-matched controls. Three peptoids were found to bind at
least 4-fold more antibodies from all of the AD patients than
any of the PD or control samples (Reddy et al., 2011). On the
microarray surface, these peptoids, especially one called
ADP3, provided good diagnostic sensitivity and specificity in a
small preliminary, open-label study of 50 patients. At about
the same time, two other reports appeared that also suggested
that there are AD-specific autoantibodies (Nagele et al., 2011;
Restrepo et al., 2011), though neither found good single
markers but rather relied on a fingerprint or algorithmic
treatment of multiple antibody-peptide or antibody-protein
complexes formed on arrays. This generated considerable
excitement, although some more recent unpublished result
from my lab suggest that the ADP3 peptoid is not a sufficiently2014 Elsevier Ltd All rights reserved 1071
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of an unacceptable level of false positives. Also, significantly
different results were observed using samples collected at
different institutions, indicating that more standardization is
required. Even more problematic is the fact that even mediocre
results are only obtained on the microarray platform, which was
custom made and had a thick layer of PEG on the surface to
block any nonspecific antibody binding. These would be difficult
to deploy for large-scale testing because their manufacture is a
tedious process, with significant batch-to-batch variation.
When ADP3 or the other peptoids were immobilized on ELISA
plates, the results were disappointing, with almost all of the
signal being due to nonspecific IgG binding to the peptoid-
coated plate (unpublished observations). This is very likely due
to the low affinity of the peptoid for the ADP3-binding antibodies
and/or the low levels of these antibodies in the serum, with the
small amount of specific signal being overwhelmed by nonspe-
cific binding. These experiments were done prior to the devel-
opment of the Luminex-inspired assay, and future efforts will
use this platform, though we are currently focused on the iden-
tification of much improved antibody ligands.
We also screened a similar peptoid library against serum sam-
ples from patients with the autoimmune neuroinflammatory dis-
ease neuromyelitis optica (NMO) (Raveendra et al., 2013). About
75% of NMO patients have autoantibodies against aquaporin 4
(AQP4) (Lennon et al., 2005), a water-transport protein found on
the surfaces of cells that line the optic nerve and are attacked in
this disease. This study used a different screening protocol quite
similar to that shown in Figure 2C, in which a library of about
100,000 peptoids synthesized on TentaGel beads were exposed
first to serum from normal patients and then, after clearing
beads that retained antibodies from the control samples, to
serum from NMO patients. This bead-based sequential
screening protocol has the advantage of allowing far more com-
pounds to be screened than is possible using the microarray
format. One of the hits, called NMOP6, proved to be a ligand
for anti-AQP4 autoantibodies and, when displayed on amicroar-
ray surface, provided excellent diagnostic sensitivity and spec-
ificity for the diagnosis of NMO in a blinded study, comparable
with that achieved using the native antigen AQP4 as the probe
(Raveendra et al., 2013). NMOP6 was also moderately effective
was used in an ELISA format. Again, significant nonspecific IgG
binding was observed, but this constituted only about 50% of
the true signal rather than overwhelming it, as was the case for
AD (B. Raveendra, W. Hao, and T.K., unpublished data), despite
the fact that the affinity of NMOP6 for a monoclonal antibody
against AQP4 is weak (>10 mM). The ability of the specific signal
to rise above the noise in the ELISA assay for NMO, but not AD,
may reflect the high levels of the NMO autoantibodies in the
serum.
Another major problem that has limited our progress over
the past few years is the high level of false positives that the
bead-screening protocol provides (Lian et al., 2013). By false
positives, I mean compounds that, at the level of the initial
bead screen, appear to be excellent ligands for antibodies found
only in the case samples, but when resynthesized and tested on
other analytical platforms, including the TentaGel bead flow
assay, display poor binding. This results in an enormous amount
of wasted time and effort resynthesizing and characterizing1072 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltscreening hits that ultimately prove useless. Thankfully, we
have recently solved this problem as well. It was shown that
these false positives are extremely low affinity antibody ligands
that happen to be displayed on a TentaGel bead of unusually
high density (the loading of individual beads in a batch of Tenta-
Gel beads varies by >20-fold) (Doran et al., 2014). This likely
traps bivalent antibodies kinetically in a microenvironment of
high ligand density even though the intrinsic affinity is terrible.
Fortunately, there is a simple solution, which is to use redundant
OBOC libraries in the screen and devote resources after
screening only to compounds isolated more than once. The
idea is that the super-high-density beads causing the problem
are rare in the population, and thus it is highly unlikely that the
same ligand found on several different beads is a false positive.
Indeed, we have found that hits isolated more than once from
redundant libraries are almost always of high quality (Doran
et al., 2014). This has accelerated our work tremendously.
Conclusions
In summary, a great deal of progress has beenmade solving vex-
ing technical issues in the serum screening process, and a new,
highly multiplexed analytical platform has been developed that
simplifies the analysis of antigen surrogate-antibody interac-
tions. Another important advance has been the development of
new classes of oligomers that are far more conformationally con-
strained than the floppy peptoids (Aditya and Kodadek, 2012;
Aquino et al., 2012; Gao and Kodadek, 2013; Sarma et al.,
2011; Suwal and Kodadek, 2013) (Figure 2A). Several screens
against antibodies and other proteins have indicated that these
new libraries are a source of much higher affinity ligands than
are peptoid libraries (Aquino et al., 2012; Gao and Kodadek,
2013). This will be important to allow the analysis of lower titer
antibodies. Other improvements are currently being explored.
For example, unrestricted use of all of the building blocks we
have developed as diversity elements in library synthesis is con-
strained by the current need to deduce hit structures by mass
spectrometry. Some linkages fragment better than others,
so the interpretation of fragmentation patterns of molecules
with mixed backbones can be challenging (Sarkar et al., 2013).
This is unfortunate, because greater scaffold diversity in these
libraries is highly desirable. Thus, we are moving toward the
development of DNA-encoded (Brenner and Lerner, 1992; Clark,
2010; Scheuermann and Neri, 2010) bead libraries that will
remove this limitation. With much improved protocols and li-
braries in hand, the next 1 to 2 years should provide a fair test
of the real utility of this approach for the discovery of antibody
biomarkers for human disease.
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